Novo Nordisk: amycretin shows promise against obesity

(CercleFinance.com) - Novo Nordisk today announced preliminary results from a phase 1b/2a clinical trial of amycretin in overweight and obese subjects.


Results showed that after 20 to 36 weeks, participants treated with amycretin lost 9.7% (1.25 mg), 16.2% (5 mg) and 22.0% (20 mg) of their body weight respectively, while those on placebo gained between 1.9% and 2.3%.

Martin Lange, Executive Vice President Development at Novo Nordisk, expressed his satisfaction with the results, saying that they support amycretin's weight-loss potential.

Following these results, Novo Nordisk plans to continue the clinical development of amycretin in overweight and obese adults.


Copyright (c) 2025 CercleFinance.com. All rights reserved.